Home LiteratureArticle Details
PMID: 24072884 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.

Molecular cancer therapeutics ·Vol. 12 ·No. 10 ·2013-10-00 ·Pages 1925-34

Bid HK, Roberts RD, Manchanda PK, Houghton PJ

Abstract

Angiogenesis and metastasis are well recognized as processes fundamental to the development of malignancy. Both processes involve the coordination of multiple cellular and chemical activities through myriad signaling networks, providing a mass of potential targets for therapeutic intervention. This review will focus on one master regulator of cell motility, RAC1, and the existing data with regard to its role in cell motility, including particular roles for tumor angiogenesis and invasion/metastasis. We also emphasize the preclinical investigations carried out with RAC1 inhibitors to evaluate the therapeutic potential of this target. Herein, we explore potential future directions as well as the challenges of targeting RAC1 in the treatment of cancer. Recent insights at the molecular and cellular levels are paving the way for a more directed and detailed approach to target mechanisms of RAC1 regulating angiogenesis and metastasis. Understanding these mechanisms may provide insight into RAC1 signaling components as alternative therapeutic targets for tumor angiogenesis and metastasis.

MeSH Terms
Cell Movement/genetics Humans Molecular Targeted Therapy Neoplasm Metastasis Neoplasms/drug therapy,genetics,pathology Neovascularization, Pathologic/drug therapy,genetics Signal Transduction rac1 GTP-Binding Protein/genetics
Chemicals
RAC1 protein, human rac1 GTP-Binding Protein
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Bid Hemant K
Corresponding Author: Peter J. Houghton, Center for Childhood Cancer, The Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205. Peter.Houghton@nationwidechildrens.org.
Roberts Ryan D
Manchanda Parmeet K
Houghton Peter J
References (71)
71 references, click to expand
  1. Role of Rho GTPases and their regulators in cancer progression.
    Front Biosci (Landmark Ed). 2011 Jun 01;16:2561-71 PMID: 21622195
  2. Mammalian Rho GTPases: new insights into their functions from in vivo studies.
    Nat Rev Mol Cell Biol. 2008 Sep;9(9):690-701 PMID: 18719708
  3. Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1.
    Circ Res. 2008 Aug 15;103(4):360-8 PMID: 18599867
  4. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.
    J Biol Chem. 2007 Dec 7;282(49):35666-78 PMID: 17932039
  5. Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.
    PLoS One. 2010 Mar 22;5(3):e9766 PMID: 20339539
  6. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  7. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size.
    Mol Cell. 2011 Apr 8;42(1):50-61 PMID: 21474067
  8. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Mol Pharmacol. 2007 Nov;72(5):1124-31 PMID: 17673571
  9. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.
    Chem Biol. 2008 Apr;15(4):322-31 PMID: 18420139
  10. Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.
    Oncogene. 2014 Feb 20;33(8):966-76 PMID: 23474757
  11. Rho GTPases and their effector proteins.
    Biochem J. 2000 Jun 1;348 Pt 2:241-55 PMID: 10816416
  12. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
    Nat Rev Cancer. 2010 Dec;10(12):842-57 PMID: 21102635
  13. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Cancer Lett. 2011 Dec 26;313(1):54-63 PMID: 21943825
  14. Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor.
    Nature. 2003 Dec 4;426(6966):525-30 PMID: 14654833
  15. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.
    Mol Cancer Ther. 2008 Nov;7(11):3490-8 PMID: 19001433
  16. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.
    Proc Natl Acad Sci U S A. 2004 May 18;101(20):7618-23 PMID: 15128949
  17. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
    Mol Cancer Ther. 2008 Apr;7(4):800-8 PMID: 18413793
  18. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.
    Breast Cancer Res. 2005;7(6):R965-74 PMID: 16280046
  19. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis.
    Oncogene. 2009 Apr 23;28(16):1853-63 PMID: 19305425
  20. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion.
    Carcinogenesis. 2007 Jun;28(6):1145-52 PMID: 17234718
  21. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck.
    Nature. 2002 Aug 15;418(6899):790-3 PMID: 12181570
  22. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.
    Nat Rev Cancer. 2003 Jun;3(6):453-8 PMID: 12778135
  23. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion.
    Oncogene. 2005 Nov 24;24(53):7821-9 PMID: 16027728
  24. Rac and Rho GTPases in cancer cell motility control.
    Cell Commun Signal. 2010 Sep 07;8:23 PMID: 20822528
  25. Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling.
    J Cell Sci. 2008 Apr 1;121(Pt 7):989-1001 PMID: 18319301
  26. MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells.
    FEBS Lett. 2011 May 6;585(9):1322-30 PMID: 21482222
  27. Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo.
    Mol Cancer Res. 2009 May;7(5):615-23 PMID: 19435813
  28. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells.
    J Cell Biol. 2010 Oct 4;191(1):169-85 PMID: 20876278
  29. Localized zones of Rho and Rac activities drive initiation and expansion of epithelial cell-cell adhesion.
    J Cell Biol. 2007 Jul 30;178(3):517-27 PMID: 17646397
  30. Spatio-temporal regulation of Rac1 localization and lamellipodia dynamics during epithelial cell-cell adhesion.
    Dev Cell. 2002 Aug;3(2):259-70 PMID: 12194856
  31. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
    Cancer Res. 2004 Jun 15;64(12):4309-18 PMID: 15205346
  32. Modes of resistance to anti-angiogenic therapy.
    Nat Rev Cancer. 2008 Aug;8(8):592-603 PMID: 18650835
  33. An essential role for Rac1 in endothelial cell function and vascular development.
    FASEB J. 2008 Jun;22(6):1829-38 PMID: 18245172
  34. Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement.
    Arthritis Rheum. 2011 Nov;63(11):3263-73 PMID: 21834066
  35. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo.
    Bioessays. 2007 Apr;29(4):356-70 PMID: 17373658
  36. PTHrP promotes colon cancer cell migration and invasion in an integrin α6β4-dependent manner through activation of Rac1.
    Cancer Lett. 2010 Dec 1;298(1):119-27 PMID: 20637541
  37. Increased Rac1b expression sustains colorectal tumor cell survival.
    Mol Cancer Res. 2008 Jul;6(7):1178-84 PMID: 18644982
  38. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.
    Cancer Cell. 2007 Nov;12(5):467-78 PMID: 17996650
  39. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors.
    Nat Rev Mol Cell Biol. 2005 Feb;6(2):167-80 PMID: 15688002
  40. Rac regulates endothelial morphogenesis and capillary assembly.
    Mol Biol Cell. 2002 Jul;13(7):2474-85 PMID: 12134084
  41. Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein.
    Mol Cancer Ther. 2010 Jun;9(6):1657-68 PMID: 20515940
  42. Ccm1 regulates microvascular morphogenesis during angiogenesis.
    J Vasc Res. 2011;48(2):130-40 PMID: 20926893
  43. Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism.
    Mol Cell. 2003 Dec;12(6):1403-11 PMID: 14690595
  44. Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach.
    Angiogenesis. 2011 Dec;14(4):457-66 PMID: 21789714
  45. Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors.
    J Am Chem Soc. 2011 Apr 20;133(15):5976-86 PMID: 21446733
  46. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.
    Oncogene. 2010 Jun 10;29(23):3335-48 PMID: 20383197
  47. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Blood. 2005 May 15;105(10):4021-7 PMID: 15665113
  48. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.
    Cancer Res. 2007 Jul 1;67(13):6092-9 PMID: 17616664
  49. The role of Rac1 in the regulation of NF-κB activity, cell proliferation, and cell migration in non-small cell lung carcinoma.
    Cancer Biol Ther. 2012 Jun;13(8):647-56 PMID: 22549160
  50. NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation.
    Oncogene. 2010 Apr 29;29(17):2540-9 PMID: 20154721
  51. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.
    Endocr Relat Cancer. 2011 Feb 23;18(2):207-19 PMID: 21118977
  52. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
    Clin Cancer Res. 2007 Aug 15;13(16):4750-8 PMID: 17699852
  53. MYC in mammalian epidermis: how can an oncogene stimulate differentiation?
    Nat Rev Cancer. 2008 Mar;8(3):234-42 PMID: 18292777
  54. Regulation of lymphatic-blood vessel separation by endothelial Rac1.
    Development. 2009 Dec;136(23):4043-53 PMID: 19906871
  55. Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer.
    BMC Cancer. 2010 Apr 28;10:164 PMID: 20426825
  56. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.
    Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7177-82 PMID: 21482786
  57. Rac1 activity regulates proliferation of aggressive metastatic melanoma.
    Exp Cell Res. 2007 Nov 1;313(18):3832-9 PMID: 17904119
  58. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.
    J Biol Chem. 2012 Apr 13;287(16):13228-38 PMID: 22383527
  59. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
    Oncogene. 2010 Oct 28;29(43):5839-49 PMID: 20711231
  60. Virtual screening approach for the identification of new Rac1 inhibitors.
    J Med Chem. 2009 Jul 23;52(14):4087-90 PMID: 19527032
  61. Tumorigenesis and the angiogenic switch.
    Nat Rev Cancer. 2003 Jun;3(6):401-10 PMID: 12778130
  62. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking.
    Trends Cell Biol. 2006 Oct;16(10):522-9 PMID: 16949823
  63. The metastatic niche: adapting the foreign soil.
    Nat Rev Cancer. 2009 Apr;9(4):285-93 PMID: 19308068
  64. Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination.
    Blood Cancer J. 2011 Jun;1(6):e21 PMID: 22829165
  65. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
    Mol Cancer Ther. 2009 Jun;8(6):1557-69 PMID: 19509242
  66. Rac1 signalling towards GLUT4/glucose uptake in skeletal muscle.
    Cell Signal. 2011 Oct;23(10):1546-54 PMID: 21683139
  67. Rac activation and inactivation control plasticity of tumor cell movement.
    Cell. 2008 Oct 31;135(3):510-23 PMID: 18984162
  68. Rac1 is a novel regulator of contraction-stimulated glucose uptake in skeletal muscle.
    Diabetes. 2013 Apr;62(4):1139-51 PMID: 23274900
  69. Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma.
    Oncogene. 2012 May 24;31(21):2640-52 PMID: 21996735
  70. Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation.
    Chem Biol. 2012 Feb 24;19(2):228-42 PMID: 22365606
  71. PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.
    Exp Neurol. 2009 Jul;218(1):137-44 PMID: 19409384
Article Info
Journal
Molecular cancer therapeutics
Abbr.
Mol Cancer Ther
ISSN
1538-8514
DOI
10.1158/1535-7163.MCT-13-0164
Email
peter.houghton@nationwidechildrens.org
Published
2013-10-00
Epub
2013-00-26
Pages
1925-34
Language
English
Region
United States
NLM ID
101132535
PMCID
PMC3823055
Subset
IM
Grants
NCI NIH HHS · P01 CA165995 · United States
NCI NIH HHS · R01 CA077776 · United States
NCI NIH HHS · CA165995 · United States
External Links
PubMed source DOI: 10.1158/1535-7163.MCT-13-0164 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2